Loading...

APUS APIMEDS PHARMACEUTICALS US INC Management Changes 8-K Filing

PMDS

PS

APIMEDS PHARMACEUTICALS US INC

(APUS)

2026 8-K

New CEO Appointment

Settlement Agreement

Delisting Notice

Filings Delay Notification

Stockholder Consent Nullified

Board Changes Invalidated

Board Restructuring

Stock Split Announcement

Director Resignations

Merger Amendment Notice

Merger Agreement

CEO Salary Increase

Bylaw Amendment

Investor Meetings

Debt Restructuring

External Links:

On May 4, 2026, Apimeds Pharmaceuticals US, Inc. appointed Sungjoon Chae as Co-Chief Executive Officer. This event marks a significant change in management, enhancing the leadership of the company.

AI Assistant

APIMEDS PHARMACEUTICALS US INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.